BioSmart Q1 revenue and profit surge; treasury share cancellation boosts shareholder value
Consolidated Q1 2026: revenue 145.3B won (+29.4% YoY), operating profit 10.1B won (+80%), net profit controlling 4.7B won (+110%)
EPS 184 won (vs 88 won in Q1 2025), doubled
Treasury shares cancellation of 889,896 shares (3.4%) in March 2026, 3B won transferred to retained earnings
Debt-to-equity ratio improved to 63% from 65% at year-end; total equity 194.9B won
Total borrowings 74B won (short-term 47B, long-term 27B); 1% interest rate change impacts pre-tax profit by 0.74B won
Major segments: heavy electrical/copper (69.8%), smart card (17.6%), pharmaceuticals (8.9%), alcohol payment (2.4%)\- Pending litigation: Koagate claims 14B won in damages, company expects immaterial impact
No dividends for past 5 years; no additional shareholder returns beyond share cancellation